Latest Bevacizumab Stories
VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/
New research report “Biosimilar Index: Tracking the Global Biosimilar Pipeline” worked out by FirstWord is now available at MarketPublishers.com London,
The Most Promising Emerging Agents in Development for Triple Negative Breast Cancer Target Only Specific Patient Subsets, According to Findings from Decision Resources Group BURLINGTON, Mass.,
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Pharmaceutical Executive Brings Additional Expertise in Oncology Drug Development and Commercialization SAN DIEGO, March 25, 2014 /PRNewswire/ --
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/llq9cw/investigation) has announced the addition of the "Investigation
LONDON, March 24, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
VANCOUVER, British Columbia and MENLO PARK, Calif., March 20, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB:
BETHLEHEM, Pa., March 20, 2014 /PRNewswire/ -- Saladax Biomedical, Inc.
CAMBRIDGE, Mass., March 18, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals,
- Emitting flashes of light; glittering.